Clinical impact of nutrition and inflammation assessment tools in pancreatic cancer treatment
T Aoyama, Y Maezawa, I Hashimoto, Y Rino… - Anticancer …, 2023 - ar.iiarjournals.org
Perioperative adjuvant treatment and complete resection is the standard treatment for
resectable pancreatic cancer and systemic chemotherapy is standard treatment for …
resectable pancreatic cancer and systemic chemotherapy is standard treatment for …
Dynamics of serum CA19-9 in patients undergoing pancreatic cancer resection
AF Van Oosten, VP Groot, G Dorland… - Annals of …, 2024 - journals.lww.com
Background: Carbohydrate antigen (CA) 19-9 is an established perioperative prognostic
biomarker for pancreatic ductal adenocarcinoma (PDAC). However, it is unclear how CA19 …
biomarker for pancreatic ductal adenocarcinoma (PDAC). However, it is unclear how CA19 …
Combination of neutrophil-to-lymphocyte ratio and serum CA 19-9 as a prognostic factor in pancreatic cancer
JS García-Herrera, WR Muñoz-Montaño… - Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Background Traditionally, serum carbohydrate antigen 19-9 (CA 19-9) has been used as a
key biomarker for pancreatic cancer and recently other biomarkers which reflect the systemic …
key biomarker for pancreatic cancer and recently other biomarkers which reflect the systemic …
Development of a biomarker-based scoring system predicting early recurrence of resectable pancreatic duct adenocarcinoma
K Ishido, N Kimura, T Wakiya, H Nagase… - Annals of Surgical …, 2022 - Springer
Background Resectable pancreatic ductal adenocarcinoma (R-PDAC) often recurs early
after radical resection, which is associated with poor prognosis. Predicting early recurrence …
after radical resection, which is associated with poor prognosis. Predicting early recurrence …
C-reactive protein and neutrophil/lymphocytes ratio: prognostic indicator for doubling overall survival prediction in pancreatic cancer patients
K Schlick, T Magnes, F Huemer, L Ratzinger… - Journal of clinical …, 2019 - mdpi.com
Background: Despite modern chemotherapy regimens, survival of patients with locally
advanced/metastatic pancreatic cancer remains dismal. Long-term survivors are rare and …
advanced/metastatic pancreatic cancer remains dismal. Long-term survivors are rare and …
Does preoperative serum Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR), and Lymphocyte to Monocyte Ratio (LMR) predict prognosis …
Background Pretherapy serum neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte
ratio (PLR), and lymphocyte to monocyte ratio (LMR) have been shown to predict prognosis …
ratio (PLR), and lymphocyte to monocyte ratio (LMR) have been shown to predict prognosis …
Identification of preoperative risk factors for poor survival in patients with resectable pancreatic cancer treated with upfront surgery
N Kondo, K Uemura, T Sumiyoshi, K Okada, S Seo… - Digestive …, 2022 - karger.com
Introduction: The aim of this study was to identify preoperative risk factors for poor survival in
patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with upfront …
patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with upfront …
[PDF][PDF] 术前白蛋白-胆红素评分以及其与CA19-9 联合作为胰腺癌患者预后指标的临床价值
范红星， 倪建勋， 薄彪， 高娴， 房启楼 - 中国普通外科杂志, 2020 - zpwz.net
摘要背景与目的: 白蛋白-胆红素(ALBI) 评分是用于评估肝细胞癌患者肝功能障碍严重程度的
指标, 但近来研究显示其与其他恶性肿瘤的预后也可能存在一定的关联. 因此 …
指标, 但近来研究显示其与其他恶性肿瘤的预后也可能存在一定的关联. 因此 …
[HTML][HTML] The Role of Resolvin D1 in the Differential Diagnosis of Pancreatic Ductal Adenocarcinoma and Acute Pancreatitis: A Case-Control Study
Background and Objectives: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive
malignancy characterized by a dense desmoplastic stroma with a poor prognosis. The aim …
malignancy characterized by a dense desmoplastic stroma with a poor prognosis. The aim …
[PDF][PDF] 术前中性粒细胞与淋巴细胞比值对胰腺癌手术患者预后价值的Meta 分析
李宛成， 姜文凯， 朱伟雄， 周文策 - 中国普通外科杂志, 2023 - zpwz.net
摘要背景与目的: 胰腺癌是恶性程度极高的实体恶性肿瘤之一, 因早期缺乏症状导致多数患者
确诊时已处于局部进展期或晚期. 因此, 探索术前判断预后的标志物对临床制定诊疗策略至关 …
确诊时已处于局部进展期或晚期. 因此, 探索术前判断预后的标志物对临床制定诊疗策略至关 …